Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood Health Plan Yuviwel Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Yuviwel (navepegritide) for Pediatric Achondroplasia

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicaid coverage and prior authorization for Yuviwel to increase linear growth in pediatric members with achondroplasia and open epiphyses. Coverage requires applicable initial or continuation criteria, absence of therapy exclusions, and compliance with quantity limits.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyYuviwel (navepegritide) for Pediatric Achondroplasia
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation of member weight, eligible prescriber specialty, FGFR3-confirmed achondroplasia, recent growth velocity, open epiphyses, medication history, surgery status, and absence of concomitant Voxzogo use.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Age 2+Minimum age for initial treatment
    ≥1.5 cm/yearRequired annualized growth velocity
    6 monthsAuthorization period
    1 vial/7 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Standard quantity limit
    2 vials/7 daysQualifying quantity exception
    Not medically necessaryOther indications

    Coverage Criteria

    Initial Therapy

    Authorization of 6 months may be granted when ALL of the following criteria are met.

    Initial therapy criteria

    • Age: Member is 2 years of age or older.≥2 years
    • Weight documentation: Documentation of the member's weight.
    • Prescriber specialty: Prescriber is an endocrinologist, pediatric endocrinologist, geneticist, or neurologist.
    • Genetic confirmation: Documentation that the diagnosis of achondroplasia was confirmed by genetic testing for an FGFR3 mutation.FGFR3 mutation confirmed by genetic testing
    • Growth documentation: Documentation of recent annualized growth velocity (AGV).
    • Open epiphyses and growth velocity: Recent documentation shows that the member has open epiphyses and a current AGV of at least 1.5 cm/year.AGV ≥1.5 cm/year
    • No recent growth-related therapy: Documentation that the member has not received growth hormone, insulin-like growth factor 1, or anabolic steroids in the past 6 months.No use in past 6 months
    • Limb-lengthening surgery status: Documentation that the member does not have planned or expected limb-lengthening surgery. Previous limb-lengthening surgery must have occurred at least 18 months before administration of Yuviwel.Previous surgery ≥18 months prior
    • No combination with Voxzogo: Member is not using Yuviwel in combination with Voxzogo.
    • Voxzogo prerequisite for higher-weight new starts: Members new to Yuviwel treatment who weigh 56 kg or greater have documented treatment failure, contraindication, or intolerance to Voxzogo.≥56 kg

      Applies to members new to Yuviwel treatment.

    Continuation Therapy

    Authorization of 6 months may be granted for continuation of therapy when ALL of the following criteria are met.

    Continuation therapy criteria

    • ONE of

      • Member has been approved for this drug by Neighborhood in the past.
      • If the member has not been approved for this drug by Neighborhood in the past, the clinician submits documentation that the initial criteria are met.
    • Weight documentation: Documentation of the member's weight.
    • Ongoing response-related findings

      • Open epiphyses:

    Coverage is limited to the FDA-approved indication of increasing linear growth in pediatric patients with achondroplasia and open epiphyses who are 2 years of age or older.

    Yuviwel must not be used in combination with Voxzogo. Concurrent therapy is excluded from coverage.

    The member must not have planned or expected limb-lengthening surgery. If limb-lengthening surgery was previously performed, it must have occurred at least 18 months before Yuviwel administration.

    Indications other than the covered FDA-approved use for pediatric achondroplasia with open epiphyses are considered experimental/investigational and not medically necessary.

    Initial Treatment of Achondroplasia

    Initial Treatment of Achondroplasia

    Authorization of 6 months may be granted for initial treatment when ALL of the following criteria are met.

    Initial treatment of achondroplasia

    • Age: Member is 2 years of age or older.≥2 years
    • Weight documentation: Documentation of the member's weight.
    • Prescriber specialty: Prescriber is an endocrinologist, pediatric endocrinologist, geneticist, or neurologist.

    Continuation of Yuviwel

    Clinical Thresholds

    Minimum age requirement
    Minimum age2 years or older
    Member populationPediatric members
    Covered conditionAchondroplasia
    Annualized growth velocity threshold
    Required current AGVAt least 1.5 cm/year
    MeasurementAnnualized growth velocity expressed in centimeters per year
    Applies toInitial and continuation therapy

    Authorization and Documentation Guidance

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial Yuviwel treatment. Authorization may be granted for 6 months when the member meets all initial approval criteria for achondroplasia, including age, clinical documentation, and applicable treatment prerequisites.

    • Member is 2 years of age or older.
    • Diagnosis is achondroplasia with open epiphyses and current annualized growth velocity (AGV) of at least 1.5 cm/year.
    • All required documentation and exclusions are addressed.
    Prior Authorization

    Continuation Prior Authorization Required

    Prior authorization is required for continuation of Yuviwel therapy. Authorization may be granted for 6 months when continuation criteria are met; if Neighborhood has not previously approved the drug, the clinician must submit documentation demonstrating that the initial criteria are met.

    • Document the member’s current weight.
    • Document open epiphyses and current AGV of at least 1.5 cm/year.

    Policy Background

    This policy addresses navepegritide (Yuviwel) for increasing linear growth in pediatric patients with achondroplasia and open epiphyses. The indication is approved under accelerated approval based on improvement in annualized growth velocity; continued approval may depend on verification and description of clinical benefit in confirmatory trials.

    Key Definitions

    Annualized growth velocity (AGV)
    DefinitionThe member's documented growth rate expressed in centimeters per year
    Policy thresholdCurrent AGV of at least 1.5 cm/year
    Coverage useRequired for initial and continuation coverage
    Open epiphyses
    DefinitionGrowth plates that remain open
    Indication relevanceRequired for the covered pediatric achondroplasia indication
    Continuation relevanceOngoing treatment requires documented open epiphyses and a current AGV of at least 1.5 cm/year

    Required Prior Therapy

    StepApplies toRequirement
    1Members new to Yuviwel treatment who weigh 56 kg or greaterDocumented treatment failure, contraindication, or intolerance to Voxzogo

    Yuviwel Quantity and Dose Limits

    Standard Yuviwel quantity limit
    Vial strengths1.3 mg, 2.8 mg, and 5.5 mg
    Standard quantity limit1 vial per 7 days
    Daily dose0.15
    Quantity-limit exception
    Exception quantity limit2 vials per 7 days
    Qualifying body weightDocumented body weight of at least 56 kg
    Qualifying weekly doses6.6 mg or 8.8 mg
    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyYuviwel (navepegritide) for Pediatric Achondroplasia
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation of member weight, eligible prescriber specialty, FGFR3-confirmed achondroplasia, recent growth velocity, open epiphyses, medication history, surgery status, and absence of concomitant Voxzogo use.
    SourceLink
    On This Page
    Coverage CriteriaInitial Treatment of AchondroplasiaContinuation of YuviwelClinical ThresholdsAuthorization and Documentation GuidancePolicy BackgroundKey DefinitionsRequired Prior TherapyYuviwel Quantity and Dose Limits
    Chart-note documentation shows that the member has open epiphyses.
  1. Current AGV: Chart-note documentation shows that the member has a current annualized growth velocity of at least 1.5 cm/year.≥1.5 cm/year
  2. Genetic confirmation:
    Documentation that the diagnosis of achondroplasia was confirmed by genetic testing for an FGFR3 mutation.
    FGFR3 mutation confirmed by genetic testing
  3. Growth documentation: Documentation of recent annualized growth velocity (AGV).
  4. Open epiphyses and growth velocity: Recent documentation shows that the member has open epiphyses and a current AGV of at least 1.5 cm/year.AGV ≥1.5 cm/year
  5. No recent growth-related therapy: Documentation that the member has not received growth hormone, insulin-like growth factor 1, or anabolic steroids in the past 6 months.No use in past 6 months
  6. Limb-lengthening surgery status: Documentation that the member does not have planned or expected limb-lengthening surgery. Previous limb-lengthening surgery must have occurred at least 18 months before administration of Yuviwel.Previous surgery ≥18 months prior
  7. No combination with Voxzogo: Member is not using Yuviwel in combination with Voxzogo.
  8. Voxzogo prerequisite for higher-weight new starts: Members new to Yuviwel treatment who weigh 56 kg or greater have documented treatment failure, contraindication, or intolerance to Voxzogo.≥56 kg

    Applies to members new to Yuviwel treatment.

  9. Higher-weight threshold
    Higher-weight thresholdAt least 56 kg
    New Yuviwel startsMembers weighing at least 56 kg must have documented treatment failure, contraindication, or intolerance to Voxzogo
    Quantity-limit exceptionQualifying members weighing at least 56 kg may receive 2 vials per 7 days when requiring a weekly dose of 6.6 mg or 8.8 mg
    Step Therapy

    Voxzogo Step Requirement

    For members new to Yuviwel treatment who weigh 56 kg or greater, the provider must document treatment failure, a contraindication, or intolerance to Voxzogo before authorization can be approved.

    • This prerequisite applies to higher-weight new starts.
    • Yuviwel must not be used in combination with Voxzogo.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Noncovered Indication or Unmet Criteria

    Coverage is limited to the FDA-approved indication: increasing linear growth in pediatric patients 2 years of age and older with achondroplasia and open epiphyses, provided all approval criteria and exclusions are satisfied. All other indications are considered experimental, investigational, and not medically necessary.

    • Requests for noncovered indications may be denied.
    • Requests that do not meet the applicable initial or continuation criteria may be denied.
    Denial Risk

    Initial Authorization Exclusions

    Initial authorization may be denied when applicable treatment exclusions are present. Confirm these conditions before submitting the request.

    • Member has received growth hormone, insulin-like growth factor 1, or anabolic steroids within the past 6 months.
    • Planned or expected limb-lengthening surgery is present; any prior limb-lengthening surgery must have occurred at least 18 months before Yuviwel administration.
    • Yuviwel is being requested in combination with Voxzogo.
    Yuviwel dose and injection volume
    Weekly dose0.88 mg
    Injection volume0.4 mL
    Vial strength1.3 mg
    Yuviwel dose and injection volume
    Weekly dose1.2 mg
    Injection volume0.55 mL
    Vial strength1.3 mg
    Yuviwel dose and injection volume
    Weekly dose1.6 mg
    Injection volume0.35 mL
    Vial strengthNot specified in the table
    Yuviwel dose and injection volume
    Weekly dose2.1 mg
    Injection volume0.45 mL
    Vial strength2.8 mg
    Yuviwel dose and injection volume
    Weekly dose2.8 mg
    Injection volume0.6 mL
    Vial strengthNot specified in the table
    Yuviwel dose and injection volume
    Weekly dose3.6 mg
    Injection volume0.65 mL
    Vial strengthNot specified in the table
    Yuviwel dose and injection volume
    Weekly dose5 mg
    Injection volume0.9 mL
    Vial strengthNot specified in the table
    Yuviwel dose and injection volume
    Weekly dose6.6 mg
    Injection volume1.2 mL using 2 kits; administer 0.6 mL from each kit
    Vial strength5.5 mg
    Yuviwel dose and injection volume
    Weekly dose8.8 mg
    Injection volume1.6 mL using 2 kits; administer 0.8 mL from each kit
    Vial strengthNot specified in the table